PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
PARSIPPANY, N.J., Sept. 19 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to PREOS(R) (parathyroid hormone [rDNA origin] for injection) f...PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
PARSIPPANY, N.J., Sept. 19 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to PREOS(R) (parathyroid hormone [rDNA origin] for injection) f...NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
...EX partnership with Nycomed, it now has the financial resources to fund the continued U.S. development of PREOS in a variety of indications, including hypoparathyroidism and osteoporosis. NPS is committed to advancing the development of PREOS in hypoparathyroidism where worldwide annual sales could exceed $200 million....